Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $127.43 million. The enterprise value is $128.09 million.
| Market Cap | 127.43M |
| Enterprise Value | 128.09M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 24.23 million shares outstanding. The number of shares has increased by 19.02% in one year.
| Current Share Class | 24.23M |
| Shares Outstanding | 24.23M |
| Shares Change (YoY) | +19.02% |
| Shares Change (QoQ) | +2.84% |
| Owned by Insiders (%) | 19.22% |
| Owned by Institutions (%) | 33.99% |
| Float | 13.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.76 |
| Forward PS | 1.68 |
| PB Ratio | 9.71 |
| P/TBV Ratio | 9.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 2.09.
| Current Ratio | 3.46 |
| Quick Ratio | 3.02 |
| Debt / Equity | 2.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.90 |
Financial Efficiency
Return on equity (ROE) is -113.88% and return on invested capital (ROIC) is -20.43%.
| Return on Equity (ROE) | -113.88% |
| Return on Assets (ROA) | -15.36% |
| Return on Invested Capital (ROIC) | -20.43% |
| Return on Capital Employed (ROCE) | -34.36% |
| Weighted Average Cost of Capital (WACC) | 16.05% |
| Revenue Per Employee | $328,614 |
| Profits Per Employee | -$82,600 |
| Employee Count | 220 |
| Asset Turnover | 1.22 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Exagen has paid $48,000 in taxes.
| Income Tax | 48,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.98% in the last 52 weeks. The beta is 2.24, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 2.24 |
| 52-Week Price Change | -44.98% |
| 50-Day Moving Average | 7.88 |
| 200-Day Moving Average | 5.12 |
| Relative Strength Index (RSI) | 33.59 |
| Average Volume (20 Days) | 501,869 |
Short Selling Information
The latest short interest is 673,850, so 2.78% of the outstanding shares have been sold short.
| Short Interest | 673,850 |
| Short Previous Month | 704,634 |
| Short % of Shares Out | 2.78% |
| Short % of Float | 5.00% |
| Short Ratio (days to cover) | 2.06 |
Income Statement
In the last 12 months, Exagen had revenue of $72.30 million and -$18.17 million in losses. Loss per share was -$0.76.
| Revenue | 72.30M |
| Gross Profit | 42.46M |
| Operating Income | -14.52M |
| Pretax Income | -18.12M |
| Net Income | -18.17M |
| EBITDA | -12.04M |
| EBIT | -14.52M |
| Loss Per Share | -$0.76 |
Balance Sheet
The company has $28.09 million in cash and $28.76 million in debt, with a net cash position of -$669,000 or -$0.03 per share.
| Cash & Cash Equivalents | 28.09M |
| Total Debt | 28.76M |
| Net Cash | -669,000 |
| Net Cash Per Share | -$0.03 |
| Equity (Book Value) | 13.78M |
| Book Value Per Share | 0.54 |
| Working Capital | 32.23M |
Cash Flow
In the last 12 months, operating cash flow was -$6.50 million and capital expenditures -$1.09 million, giving a free cash flow of -$7.59 million.
| Operating Cash Flow | -6.50M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 2.48M |
| Net Borrowing | -1.41M |
| Free Cash Flow | -7.59M |
| FCF Per Share | -$0.31 |
Margins
Gross margin is 58.74%, with operating and profit margins of -20.08% and -25.14%.
| Gross Margin | 58.74% |
| Operating Margin | -20.08% |
| Pretax Margin | -25.07% |
| Profit Margin | -25.14% |
| EBITDA Margin | -16.65% |
| EBIT Margin | -20.08% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.02% |
| Shareholder Yield | -19.02% |
| Earnings Yield | -14.44% |
| FCF Yield | -5.95% |
Analyst Forecast
The average price target for Exagen is $10.57, which is 100.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.57 |
| Price Target Difference | 100.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 10.67% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |